GeoVax’s COVID-19 vaccine candidates, which can induce strong antibody and T cell responses against the variants of the SARS-CoV-2 virus, also offers the possibility of protection against Monkey pox and smallpox diseases, further differentiating GEO-CM04S1 as compared to current mRNA-based COVID-19 vaccines.

Such attributes may be especially important in vulnerable patient populations, such as the millions of immune-compromised patients.